Kornimate/medical-research-clean huggingface dataset:
oral clonidine & gabapentin: improving recovery and pain management after outpatient with major orthopedic surgery

Conditions: Shoulder Arthroscopy; Knee Arthroscopy

Summary: the purpose of this research is to investigate the non-opioid (non-narcotic) pain-relieving medications clonidine and gabapentin to see if they decrease the amount of opioid pain medications needed after surgery, thereby reducing opioid-related side effects, and time required to return to normal activities of daily living after surgery.


Eligibility criteria:
inclusion criteria: * patients scheduled to undergo arthroscopic joint surgery * willingness and ability to sign an informed consent document * no allergies to clonidine, gabapentin, anesthetic or analgesic medications * 18 - 80 years of age * american society of anesthesiologists (asa) class i - iii adults of either sex * women of childbearing potential must be currently practicing an acceptable form of birth control, and have a negative urine pregnancy test exclusion criteria: * patients with known allergy, hypersensitivity or contraindications to clonidine, gabapentin, anesthetic or analgesic medications * patients with clinically-significant medical conditions, such as brain, heart, kidney, endocrine, or liver diseases, peptic ulcer disease or bleeding disorders * patients with chronic hypertension or pain syndromes receiving clonidine or gabapentin, respectively. * pregnant or lactating women * subjects with a history of alcohol or drug abuse within the past 3 months * patients taking any analgesic medications within 48 hours prior to the surgery * any other conditions or use of any medication which may interfere with the conduct of the study * non-english speakers * patients greater than 80 years of age

Keywords: shoulder arthroscopy knee arthroscopy clonidine gabapentin pain management ambulatory surgery perioperative outcome analgesia
effect of prophylactic application of 40hz transcranial stimulation in aicu on incidence of postoperative delirium in elderly patients undergoing elective gastrointestinal surgery

Conditions: Postoperative Delirium; Anesthesia; Elderly

Summary: postoperative delirium is an acute central nervous system dysfunction caused by surgical stress, which is manifested by postoperative acute, non-specific changes in consciousness level, attention, cognitive ability and disturbance of sleep and wake cycles. it is one of the most common surgical complications in the elderly, occurring in more than 75% of patients receiving mechanical ventilation in the intensive care unit(icu).exogenous 40 hz stimulation can improve cognitive functioning.therefore, the aim of this study was to investigate the effect of exogenous 40hz stimulation on the incidence of postoperative delirium in elderly patients undergoing elective gastrointestinal surgery in aicu.


Eligibility criteria:
inclusion criteria: * 1.age ≥ 65 years old,gender not limited * 2.asa classification ⅱ \~ ⅳ * 3.elective gastrointestinal general anesthesia surgery exclusion criteria: * 1.history of schizophrenia, epilepsy, parkinson's disease, or myasthenia gravis * 2.pre-operative coma, severe dementia, speech impairment or severe illness incapacitated and unable to communicate * 3.delirium on admission or pre-operative delirium, brain injury * 4.severely infected person * 5.severe liver dysfunction (child-pugh c), severe renal insufficiency (preoperative dialysis) * 6.severe hearing or vision impairment
cerebral near-infrared spectroscopy (nirs) monitoring throughout caesarean deliveries

Conditions: Anoxia

Summary: in this study the investigator would like to examine hemodynamic cerebral blood flow and brain function by the use of invos cerebral oximetry in women undergoing cesarean section delivery. this study is a purely observational study, it will not have any clinical intervention nor will it interfere with standard cesarean delivery protocols in any way. the investigator's primary objective is to evaluate how anesthesia influences cerebral blood flow perfusion during cesarean section deliveries.

this is a prospective, single center study which will be conducted at the rabin medical center (beilinson campus), petach tikva, israel, a tertiary university hospital. the institutional review board has approved this study. two hundred women undergoing cesarean sections will be enrolled after filling out an informed consent form. cerebral blood flow perfusion will be monitored preoperatively, intraoperativly and half an hour postoperativly, for all enrolled participants using invos cerebral oximetry. preoperative data will be compared to intraoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in women undergoing cesarean sections.

Eligibility criteria:
inclusion criteria: * all women undergoing cesarean section in beilinson hospital following obtaining written informed consents forums with the ability to comply to the study requirements will be included in our study. exclusion criteria: * women under age 18 , and women who don't understand the inform consent form will be excluded from participating.

Keywords: during labor complicating anesthesia or other sedation cerebral
clinical trial to evaluate biafine cream versus standard care in subjects with actinic keratosis post cryotherapy

Conditions: Actinic Keratosis

Summary: the purpose of this research study is to evaluate the use of biafine cream on wounds created by removal of actinic keratosis using cryotherapy in a clinical setting.

subjects were randomized to apply biafine® to wounds on one forearm and polysporin (standard of care) to wounds on the other. medications were applied three times a day for 4 weeks to the areas that have been treated with cryotherapy at the baseline visit.

Eligibility criteria:
inclusion criteria: * subject must give written consent. * subjects must be \>50 years of age, male or female. * subjects must have had cryotherapy treatment of at least one ak's on each forearm in the dermatology clinic. exclusion criteria: * subjects age \<50 years of age. * subjects with known allergy or sensitivity to topical biafine or polysporin ointment. * inability to complete all study-related visits. * introduction of any other prescription medication, topical or systemic, for ak while participating in the study. * subjects using other topical agent's glycolic acid products, alpha-hydroxy acid products, retinoids and chemical peel agents in the treatment areas while on study.
flucelvax pregnancy registry

Conditions: Pregnant Women, Influenza

Summary: the goal of the registry is to develop a better understanding of the safety of flucelvax in women and their offspring who were exposed to the vaccine during pregnancy


Eligibility criteria:
inclusion criteria: * pregnancy women pregnant women aged 18 years or older within the us who were immunized with the flucelvax vaccine at any time during pregnancy.the registry will allow eligible pregnant women to selfenroll and also allow hcps to report de-identified data on pregnancy exposures and outcomes. * sufficient evidence to confirm that flucelvax exposure occurred during pregnancy * sufficient information to determine whether the pregnancy is prospectively or retrospectively registered (ie, whether the outcome of pregnancy was known at the time of first contact with the registry) * date the pregnancy exposure is registered * full reporter (ie, hcp) contact information to allow for follow-up (name, address,etc) the primary population for analysis will include prospectively enrolled pregnancies exposed to flucelvax that are not lost to follow-up (ie, with outcome information that meet the minimum criteria for evaluation) exclusion criteria: * invalid registry reports and pregnancies deemed lost to follow-up will be excluded from the primary analysis. retrospective reports will not be included, although retrospective cases with mcms will be reviewed and reported separately.
a study of ibi363 in subjects with advanced solid malignancies

Conditions: Melanoma; Non-small Cell Lung Cancer; Colorectal Cancer; Renal Cell Cancer

Summary: this is a phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of ibi363 (study drug) in subjects with advanced, refractory solid malignancies.


Eligibility criteria:
inclusion criteria: 1. subjects have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol; 2. male or female subjects ≥ 18 years old; 3. eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1; 4. anticipated life expectancy of ≥ 3 months; exclusion criteria: 1. inadequate bone marrow and organ function; 2. received previous anti-tumor therapy: any chemotherapy or targeted small molecule therapy (standard or investigational) within 2 weeks or 5 plasma half-lives. received nitrosoureas and mitomycin c within 6 weeks prior to first dose of study drug and during study; any anti-cancer monoclonal antibody (mab) within 4 weeks prior to first dose 3. received live vaccines within 28 days prior to first administration of the study drug or plan on receiving any live vaccine during the study; 4. has adverse reactions resulting from previous antitumor therapies, which have not resolved to grade 0 or 1 toxicity according to nci-ctcae v5.0 (except for alopecia, fatigue, pigmentation and other conditions with no safety risk according to investigator' discretion) or baseline prior to the first dose of the study drug; 5. undergone major surgery (craniotomy, thoracotomy or laparotomy, and other surgery according to investigator' discretion, excluding needle biopsy) within 4 weeks prior to the first dose of the study drug, or who are expected to undergo major surgery during the study period, or who have severe unhealed wounds, trauma, ulcers, etc.
sedpark1: safety and efficacy study with the non-ergot dopamine-agonist piribedil in parkinson's disease

Conditions: Parkinson's Disease

Summary: the aim of the non-interventional post marketing study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: clarium) in mono- and combination therapy in patients with morbus parkinson. tolerability and course of the disease or change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonists will be documented under routine conditions. piribedil should be prescribed according to its marketing authorisation by the responsible neurologist.


Eligibility criteria:
inclusion criteria: * male and female patients 18 years and older. * indication: morbus parkinson. * treatment with piribedil for the first time. * monotherapy with piribedil. * combination therapy with l-dopa (from the beginning or secondary) and/or in combination with other antiparkinsonian drugs. exclusion criteria:

Keywords: piribedil (trade name: clarium) non-ergot dopamine agonist morbus parkinson tolerability efficacy post marketing surveillance
hiv testing in non-traditional settings study

Conditions: HIV

Summary: surveillance data suggests that approximately one third of the 82 000 hiv infected adults in the uk remain undiagnosed - that is, they are living with the infection but do not know this. the majority of hiv testing in the uk to date has taken place in sexual health clinics and in antenatal care. published national guidelines advocate routine hiv testing of 16-65 year olds in more general healthcare settings in parts of the country with relatively high rates of hiv (more than 2 per thousand individuals diagnosed locally). the hints study investigates the utility, feasibility and acceptability, to patients and staff, of offering routine hiv testing in four general medical settings, all set in areas of high hiv prevalence. the settings comprise: primary care, outpatients, an acute care unit and an emergency department.


Eligibility criteria:
inclusion criteria (patient study only): * aged 16 - 65 and accessing relevant healthcare setting for care * able to consent to hiv test * able to provide adequate contact details * to complete written questionnaire: adequate written english * to participate in focus group discussion (pre-study group)/participate in semi-structured telephone interview (intra-study group): ability to provide fully informed consent exclusion criteria: * known hiv positive * unable to provide adequate contact details * unable to provide consent (to hiv test and/or participation in questionnaire/focus group/semi-structured interview studies)

Keywords: hiv testing non traditional settings acceptability feasibility
intravenous immunoglobulin (ivig) versus plasma exchange (pe) for ventilated children with guillain barre syndrome (gbs)

Conditions: Guillain Barre Syndrome

Summary: comparing whether intravenous immune globulin or plasma exchange is superior in treating mechanically ventilated children with guillain barre syndrome.

children with guillain barre syndrome (gbs) admitted to picu at mansoura university children hospital, mansoura, egypt with the need for mechanical ventilation were prospectively enrolled in the study. cases were diagnosed according to clinical criteria. the decisions to initiate, wean and terminate mechanical ventilation were made independently by the attending consultant in accordance with the unit guidelines. outcome variables measured were duration of mechanical ventilation, length of picu stay and ability to walk unaided 4 weeks after picu discharge.

Eligibility criteria:
inclusion criteria: * age: children from 1 month - 18 years old * clinical diagnosis of guillain barre syndrome * requirement of mechanical ventilation exclusion criteria: * need for mechanical ventilation beyond 14 days from disease onset * child receiving ivig or pe prior to enrollment

Keywords: guillain barre syndrome ivig plasma exchange
exercise facilitation of adolescent fear extinction, frontolimbic circuitry, and endocannabinoids

Conditions: Adolescence

Summary: anxiety disorders commonly begin during adolescence, and are characterized by deficits in the ability to inhibit or extinguish pathological fear. recent research has provided new understanding of how fear is learned and can be regulated in the adolescent brain, and how the endocannabinoid system shapes these processes; however, these advances have not yet translated into improved therapeutic outcomes for adolescents with anxiety. this study will test whether a behavioral intervention, acute exercise, can help to improve fear regulation by enhancing brain activity and endocannabinoid signaling. this line of research may ultimately lead to more effect treatments for adolescent anxiety, and to new preventive strategies for at-risk youth.


Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and available for the duration of the study 3. 14-17 years of age upon enrollment 4. right-handed 5. in good general health as evidenced by medical history 6. adolescent and parent/guardian are english-speaking, as study assessments are in english 7. availability of a parent or legal guardian who is willing to provide consent and attend all study visits exclusion criteria: 1. traumatic brain injury with ongoing symptoms 2. sensory (e.g., hearing) or physical (e.g., motor, balance) impairment or significant developmental delay 3. mri participants: mri contraindication (e.g., braces, implants, claustrophobia) 4. any condition that would contraindicate blood draws (e.g., hemophilia, sickle cell) 5. past or current diagnosis or presence of likely neurological disorder (e.g., epilepsy), psychotic disorder (e.g., schizophrenia, schizoaffective disorder), or bipolar disorder 6. severe/unstable medical condition (e.g., diabetes, rheumatoid arthritis) 7. current (past 1-month) use of cannabis or cannabinoid products including cbd unless willing to stop for at least 4 weeks prior to entering the study 8. currently pregnant, lactating, or positive pregnancy test at screening visit 9. current homicidal thoughts or suicide attempt in the past year 10. current suicidal thoughts requiring immediate intervention 11. concurrent use (past 6 weeks) of oral contraceptives 12. diagnosed or probable substance use disorder (past 1-month) 13. positive drug test at baseline visit (e.g., thc, cocaine) 14. moderate/severe drug or alcohol use in the past 8 weeks 15. current or recent (past 1-month) covid-19 diagnosis or febrile illness 16. treatment with investigational drug or intervention (past 1-month) 17. current smoker, vaper, or tobacco or nicotine use (past 1-month) 18. ongoing exposure to abuse

Keywords: anxiety exercise fear
the effect of dexamethasone in combination with paracetamol and ibuprofen on postoperative pain after spine surgery

Conditions: Pain

Summary: the analgesic effect of dexamethasone is not well described, but studies have shown that dexamethasone can be a safe part of a multimodal analgesic strategy after surgery. our purpose is to investigate if dexamethasone in combination with paracetamol and ibuprofen has an increased analgesic effect compared to paracetamol and ibuprofen alone, on postoperative pain after spine surgery. our hypothesis is that dexamethasone can reduce postoperative pain and reduce opioidconsumption and side effects compared to placebo.

the analgesic effect of dexamethasone is not well described, but studies have shown that an intermediate dosis of dexamethasone (0.11-0.2 mg/kg) can be a safe part of a multimodal analgesic strategy after surgery. dexamethasone has an opioid-sparing effect and reduces pain during rest and mobilisation. our purpose is to investigate if dexamethasone in combination with paracetamol and ibuprofen has an increased analgesic effect compared to paracetamol and ibuprofen alone, on postoperative pain after herniated disk surgery. our hypothesis is that dexamethasone can reduce postoperative pain and reduce opioidconsumption and side effects compared to placebo.

Eligibility criteria:
inclusion criteria: * patients undergoing lumbar disc surgery in general anaesthesia. * patients who have given their written consent to participate and understand the contents of the protocol. * asa 1-3. * bmi \> 18 og \< 40. * fertile women need a negative hcg urine test. exclusion criteria: * patients who cannot cooperate to the study. * patients who do not speak and/or understand danish. * fertile women with a positive hcg urine test. * allergy to the drugs used in the trial. * alcohol or medicine abuse, assessed by investigator. * patients who have had spine surgery before. * daily use of strong opioids (morphine, ketobemidone, oxynorm, methadone, fentanyl) * daily oral steroid treatment.

Keywords: pain analgesia postoperative dexamethasone spine surgery
a study of kytril (granisetron) in the prevention of post-operative nausea and vomiting (ponv) in pediatric subjects undergoing tonsillectomy or adenotonsillectomy

Conditions: Post-Operative Nausea and Vomiting

Summary: this 2 arm study will evaluate the efficacy and safety of a single intravenous injection of kytril in preventing postoperative nausea and vomiting (ponv) in children. patients will be randomized to receive a single dose of either 20 micrograms or 40 micrograms kytril intravenously (iv) 15 minutes prior to the end of surgery with general anesthesia for tonsillectomy or adenotonsillectomy. the anticipated time on study treatment is \<3 months, and the planned sample size was 170 patients.


Eligibility criteria:
inclusion criteria: * males and females 2-16 years of age * scheduled to undergo elective surgery for tonsillectomy or adenotonsillectomy requiring general anesthesia and endotracheal intubation * scheduled for hospital admission for no longer than 24 hours exclusion criteria: * known allergy or other contraindication to the use of kytril or any of its components * known allergy to any other 5ht3 antagonist * history of motion sickness or post-operative nausea or vomiting * nausea or vomiting in the 24 hours prior to anesthesia
quality of life in patients with hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is the sixth most common cancer and the second leading cause of cancer-related mortality worldwide. despite the recent advances in the treatment of hcc, the prognosis of hcc is still poor even after curative treatment. performance status has shown to be associated with long-term survival and prognosis in patients with hcc, and it is one of the important factors in the barcelona clinic liver cancer (bclc) staging system. recently, the researches on health-related quality of life (hrql) of cancer patients have been progressed. the most widely used surveys to assess hrql of cancer patients are functional assessment of cancer therapy-generic (fact-g) and european organisation for research and treatment of cancer (eortc) quality of life questionnaire (qlq)-c30. since those two are mainly about cancers in general, hcc specific surveys were developed. the fact-hep questionnaire has 45-items specifically focusing on patients with hepatobiliary cancers. eortc qlq-hepatocellular carcinoma 18 (hcc 18) is an 18-item questionnaire designed to be used along with the eortc qlq-c30 for patients with hcc. an 18-item national comprehensive cancer network (nccn)-fact hepatobiliary-pancreatic symptom index (nfhsi-18) is a specific questionnaire for advanced hepatobiliary and pancreatic cancers. however, there is no consensus whether it would be appropriate to adopt hrql as a prognostic variable in hcc staging system. moreover, there is limited information available about the impact of patients' hrql on long-term outcome in patients with hcc. thus, in this study, the researchers will investigate whether hrql can be an important factor in hcc staging system by testing the reliability and clinical validity of fact-hep, eortc qlq-hcc18, and nfhsi-18. second, the investigators will evaluate the relation of hrql with treatment efficacy, recurrence and survival outcome. lastly, the investigators will suggest the suitable questionnaire module for patients with hcc.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * diagnosis of hcc * ability to speak, read, and write korean * patient is able and willing to give informed consent exclusion criteria: * evidence of cognitive impairment or psychiatric disturbance * other concurrent malignancy * patients involved in other clinical studies
effect of dexamethasone and epinephrine on the duration of sciatic nerve blocks with ropivacaine

Conditions: Postoperative Pain

Summary: the aim of the present study is to test that adding dexamethasone or epinephrine significantly prolongs the duration of sciatic nerve blocks with ropivacaine and that the magnitude of the effect differs among dexamethasone and epinehrine.

in a double-blinded trial utilizing single-injection sciatic nerve block, patients are randomly assigned to one of three groups: control: 0.5% ropivacaine adding normal saline; epinephrine: 0.5% ropivacaine adding epinephrine; dexamethasone: 0.5% ropivacaine adding dexamethasone. we assess time to first analgesic request after post-anaesthesia care unit discharge.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status i and ii * patients undergoing elective hallux valgus repair exclusion criteria: * patients receiving chronic analgesic therapy * diabetes * peripheral neuropathies * psychiatric disorders * hypersensitivity to amide local anesthetics * renal disorders